Large-scale international validation of the ADO index in subjects with COPD

An individual subject data analysis of 10 cohorts

Milo A. Puhan, Nadia Hansel, Patricia Sobradillo, Paul Enright, Peter Lange, Demarc Hickson, Ana M. Menezes, Gerben Ter Riet, Ulrike Held, Antonia Domingo-Salvany, Zab Mosenifar, Josep M. Antó, Karel G M Moons, Alphons Kessels, Judith Garcia-Aymerich

Research output: Contribution to journalArticle

Abstract

Background: Little evidence on the validity of simple and widely applicable tools to predict mortality in patients with chronic obstructive pulmonary disease (COPD) exists. Objective: To conduct a large international study to validate the ADO index that uses age, dyspnoea and FEV1 to predict 3-year mortality and to update it in order to make prediction of mortality in COPD patients as generalisable as possible. Design: Individual subject data analysis of 10 European and American cohorts (n=13 914). Setting: Population-based, primary, secondary and tertiary care. Patients: COPD GOLD stages I-IV. Measurements: We validated the original ADO index. We then obtained an updated ADO index in half of our cohorts to improve its predictive accuracy, which in turn was validated comprehensively in the remaining cohorts using discrimination, calibration and decision curve analysis and a number of sensitivity analyses. Results: 1350 (9.7%) of all subjects with COPD (60% male, mean age 61 years, mean FEV1 66% predicted) had died at 3 years. The original ADO index showed high discrimination but poor calibration (p1 alone. Interpretation: The updated 15-point ADO index accurately predicts 3-year mortality across the COPD severity spectrum and can be used to inform patients about their prognosis, clinical trial study design or benefit harm assessment of medical interventions.

Original languageEnglish (US)
Article numbere002152
JournalBMJ Open
Volume2
Issue number6
DOIs
StatePublished - 2012

Fingerprint

Chronic Obstructive Pulmonary Disease
Mortality
Calibration
Secondary Care
Decision Support Techniques
Tertiary Healthcare
Dyspnea
Primary Health Care
beta-apocarotenoid-14',13'-dioxygenase
Clinical Trials
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Large-scale international validation of the ADO index in subjects with COPD : An individual subject data analysis of 10 cohorts. / Puhan, Milo A.; Hansel, Nadia; Sobradillo, Patricia; Enright, Paul; Lange, Peter; Hickson, Demarc; Menezes, Ana M.; Riet, Gerben Ter; Held, Ulrike; Domingo-Salvany, Antonia; Mosenifar, Zab; Antó, Josep M.; Moons, Karel G M; Kessels, Alphons; Garcia-Aymerich, Judith.

In: BMJ Open, Vol. 2, No. 6, e002152, 2012.

Research output: Contribution to journalArticle

Puhan, MA, Hansel, N, Sobradillo, P, Enright, P, Lange, P, Hickson, D, Menezes, AM, Riet, GT, Held, U, Domingo-Salvany, A, Mosenifar, Z, Antó, JM, Moons, KGM, Kessels, A & Garcia-Aymerich, J 2012, 'Large-scale international validation of the ADO index in subjects with COPD: An individual subject data analysis of 10 cohorts', BMJ Open, vol. 2, no. 6, e002152. https://doi.org/10.1136/bmjopen-2012-002152
Puhan, Milo A. ; Hansel, Nadia ; Sobradillo, Patricia ; Enright, Paul ; Lange, Peter ; Hickson, Demarc ; Menezes, Ana M. ; Riet, Gerben Ter ; Held, Ulrike ; Domingo-Salvany, Antonia ; Mosenifar, Zab ; Antó, Josep M. ; Moons, Karel G M ; Kessels, Alphons ; Garcia-Aymerich, Judith. / Large-scale international validation of the ADO index in subjects with COPD : An individual subject data analysis of 10 cohorts. In: BMJ Open. 2012 ; Vol. 2, No. 6.
@article{bb83420fdd0e485abd2ccaa4c68b29e5,
title = "Large-scale international validation of the ADO index in subjects with COPD: An individual subject data analysis of 10 cohorts",
abstract = "Background: Little evidence on the validity of simple and widely applicable tools to predict mortality in patients with chronic obstructive pulmonary disease (COPD) exists. Objective: To conduct a large international study to validate the ADO index that uses age, dyspnoea and FEV1 to predict 3-year mortality and to update it in order to make prediction of mortality in COPD patients as generalisable as possible. Design: Individual subject data analysis of 10 European and American cohorts (n=13 914). Setting: Population-based, primary, secondary and tertiary care. Patients: COPD GOLD stages I-IV. Measurements: We validated the original ADO index. We then obtained an updated ADO index in half of our cohorts to improve its predictive accuracy, which in turn was validated comprehensively in the remaining cohorts using discrimination, calibration and decision curve analysis and a number of sensitivity analyses. Results: 1350 (9.7{\%}) of all subjects with COPD (60{\%} male, mean age 61 years, mean FEV1 66{\%} predicted) had died at 3 years. The original ADO index showed high discrimination but poor calibration (p1 alone. Interpretation: The updated 15-point ADO index accurately predicts 3-year mortality across the COPD severity spectrum and can be used to inform patients about their prognosis, clinical trial study design or benefit harm assessment of medical interventions.",
author = "Puhan, {Milo A.} and Nadia Hansel and Patricia Sobradillo and Paul Enright and Peter Lange and Demarc Hickson and Menezes, {Ana M.} and Riet, {Gerben Ter} and Ulrike Held and Antonia Domingo-Salvany and Zab Mosenifar and Ant{\'o}, {Josep M.} and Moons, {Karel G M} and Alphons Kessels and Judith Garcia-Aymerich",
year = "2012",
doi = "10.1136/bmjopen-2012-002152",
language = "English (US)",
volume = "2",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Large-scale international validation of the ADO index in subjects with COPD

T2 - An individual subject data analysis of 10 cohorts

AU - Puhan, Milo A.

AU - Hansel, Nadia

AU - Sobradillo, Patricia

AU - Enright, Paul

AU - Lange, Peter

AU - Hickson, Demarc

AU - Menezes, Ana M.

AU - Riet, Gerben Ter

AU - Held, Ulrike

AU - Domingo-Salvany, Antonia

AU - Mosenifar, Zab

AU - Antó, Josep M.

AU - Moons, Karel G M

AU - Kessels, Alphons

AU - Garcia-Aymerich, Judith

PY - 2012

Y1 - 2012

N2 - Background: Little evidence on the validity of simple and widely applicable tools to predict mortality in patients with chronic obstructive pulmonary disease (COPD) exists. Objective: To conduct a large international study to validate the ADO index that uses age, dyspnoea and FEV1 to predict 3-year mortality and to update it in order to make prediction of mortality in COPD patients as generalisable as possible. Design: Individual subject data analysis of 10 European and American cohorts (n=13 914). Setting: Population-based, primary, secondary and tertiary care. Patients: COPD GOLD stages I-IV. Measurements: We validated the original ADO index. We then obtained an updated ADO index in half of our cohorts to improve its predictive accuracy, which in turn was validated comprehensively in the remaining cohorts using discrimination, calibration and decision curve analysis and a number of sensitivity analyses. Results: 1350 (9.7%) of all subjects with COPD (60% male, mean age 61 years, mean FEV1 66% predicted) had died at 3 years. The original ADO index showed high discrimination but poor calibration (p1 alone. Interpretation: The updated 15-point ADO index accurately predicts 3-year mortality across the COPD severity spectrum and can be used to inform patients about their prognosis, clinical trial study design or benefit harm assessment of medical interventions.

AB - Background: Little evidence on the validity of simple and widely applicable tools to predict mortality in patients with chronic obstructive pulmonary disease (COPD) exists. Objective: To conduct a large international study to validate the ADO index that uses age, dyspnoea and FEV1 to predict 3-year mortality and to update it in order to make prediction of mortality in COPD patients as generalisable as possible. Design: Individual subject data analysis of 10 European and American cohorts (n=13 914). Setting: Population-based, primary, secondary and tertiary care. Patients: COPD GOLD stages I-IV. Measurements: We validated the original ADO index. We then obtained an updated ADO index in half of our cohorts to improve its predictive accuracy, which in turn was validated comprehensively in the remaining cohorts using discrimination, calibration and decision curve analysis and a number of sensitivity analyses. Results: 1350 (9.7%) of all subjects with COPD (60% male, mean age 61 years, mean FEV1 66% predicted) had died at 3 years. The original ADO index showed high discrimination but poor calibration (p1 alone. Interpretation: The updated 15-point ADO index accurately predicts 3-year mortality across the COPD severity spectrum and can be used to inform patients about their prognosis, clinical trial study design or benefit harm assessment of medical interventions.

UR - http://www.scopus.com/inward/record.url?scp=84873883218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873883218&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2012-002152

DO - 10.1136/bmjopen-2012-002152

M3 - Article

VL - 2

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 6

M1 - e002152

ER -